



# Dr. Irina Bergamin

## contact

<b>titel</b>	Dr.med.
<b>first name</b>	Irina
<b>last name</b>	Bergamin
<b>country</b>	Switzerland
<b>phone number</b>	+41 71 494 7325
<b>e-mail</b>	<a href="mailto:irina.bergamin@kssg.ch">irina.bergamin@kssg.ch</a>

## publications

### title

---

**journal  
paper/  
review**

Seidl S, Bergamin I, Boggian K, Meuthen T. Hepatosplenische Schistosomiasis. Swiss Medical Forum 2019; 19:824-826.

---

Baumeler S, Jochum W, Neuweiler J, Bergamin I, Semela D. Controlled attenuation parameter for the assessment of liver steatosis in comparison with liver histology: a single-centre real life experience. Swiss Med Wkly 2019; 149:w20077.

---

Bachofner J, Valli P V, Bergamin I, Kröger A, Künzler-Heule P, Baserga A, Braun D L, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Müllhaupt B, Terzioli Beretta-Piccoli B, Mertens J, The Swiss Hepatitis C Cohort Study . Excellent outcome of direct antiviral treatment for chronic hepatitis C in Switzerland. Swiss Med Wkly 2018; 148:w14560.

---

Bachofner J A, Valli P V, Kröger A, Bergamin I, Künzler-Heule P, Baserga A, Braun D, Seifert B, Moncsek A, Fehr J, Semela D, Magenta L, Terzioli Beretta-Piccoli B, Müllhaupt B, Mertens J C. DAA treatment of chronic hepatitis C results in rapid regression of transient elastography and fibrosis markers FIB-4 and APRI. Liver Int 2016;.



## projects

title	status
Evaluation of Controlled Attenuated Parameter (CAP) for Assessment of Liver Steatosis in an Unselected Population: a Single Center Real Life Experience	completed